Lineage Cell Therapeutics: Q1 Earnings Insights
Lineage Cell Therapeutics: Q1 Earnings Insights
Lineage Cell Therapeutics (AMEX:LCTX) reported its Q1 earnings results on Thursday, May 11, 2023 at 04:01 PM.
Here's what investors need to know about the announcement.
Earnings
Lineage Cell Therapeutics beat estimated earnings by 25.0%, reporting an EPS of $-0.03 versus an estimate of $-0.04.
Revenue was down $2.85 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.01 which was followed by a 2.05% drop in the share price the next day.
Here's a look at Lineage Cell Therapeutics's past performance:
Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
---|---|---|---|---|
EPS Estimate | -0.04 | -0.03 | -0.04 | -0.03 |
EPS Actual | -0.03 | -0.04 | -0.04 | -0.04 |
Revenue Estimate | 2.57M | 3.90M | 3.68M | 7.32M |
Revenue Actual | 1.90M | 3.00M | 4.55M | 5.24M |
To track all earnings releases for Lineage Cell Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Lineage Cell Therapeutics (AMEX:LCTX) reported its Q1 earnings results on Thursday, May 11, 2023 at 04:01 PM.
谱系细胞疗法 (AMEX: LCTX) 于 2023 年 5 月 11 日星期四下午 4:01 公布了第一季度财报。
Here's what investors need to know about the announcement.
以下是投资者需要了解的有关该公告的信息。
Earnings
收益
Lineage Cell Therapeutics beat estimated earnings by 25.0%, reporting an EPS of $-0.03 versus an estimate of $-0.04.
Lineage Cell Therapeutics的收益比预期高出25.0%,报告的每股收益为-0.03美元,而预期为-0.04美元。
Revenue was down $2.85 million from the same period last year.
收入比去年同期下降了285万美元。
Past Earnings Performance
过去的收益表现
Last quarter the company beat on EPS by $0.01 which was followed by a 2.05% drop in the share price the next day.
上个季度,该公司的每股收益比每股收益高出0.01美元,随后第二天股价下跌了2.05%。
Here's a look at Lineage Cell Therapeutics's past performance:
以下是Lineage Cell Therapeutics过去的表现:
Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
---|---|---|---|---|
EPS Estimate | -0.04 | -0.03 | -0.04 | -0.03 |
EPS Actual | -0.03 | -0.04 | -0.04 | -0.04 |
Revenue Estimate | 2.57M | 3.90M | 3.68M | 7.32M |
Revenue Actual | 1.90M | 3.00M | 4.55M | 5.24M |
季度 | 2022 年第四季度 | 2022 年第三季度 | 2022 年第二季度 | 2022年第一季度 |
---|---|---|---|---|
每股收益估算 | -0.04 | -0.03 | -0.04 | -0.03 |
实际每股收益 | -0.03 | -0.04 | -0.04 | -0.04 |
收入估算 | 2.57M | 3.90 米 | 3.68M | 7.32M |
实际收入 | 1.90 米 | 3.00M | 4.55M | 5.24M |
To track all earnings releases for Lineage Cell Therapeutics visit their earnings calendar here.
要追踪Lineage Cell Therapeutics发布的所有财报,请在此处访问他们的财报日历。
This article was generated by Benzinga's automated content engine and reviewed by an editor.
本文由Benzinga的自动内容引擎生成,并由编辑审阅。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧